Altimmune
(NASDAQ:ALT)
$11.28
0.49[4.54%]
At close: Dec 2(Delayed 15-Minutes)
Get Real Time Here
$11.44
0.1600[1.42%]
After Hours: 6:41PM EDT
Day Range10.53 - 11.3352 Wk Range3.83 - 23.49Open / Close10.65 / 11.28Float / Outstanding48.8M / 49.2M
Vol / Avg.1.1M / 2.3MMkt Cap554.5MP/E-50d Avg. Price10.98
Div / Yield-Payout Ratio-Total Float48.8MEPS-0.48

Altimmune Stock (NASDAQ:ALT), Quotes and News Summary

Altimmune Stock (NASDAQ: ALT) stock price, news, charts, stock research, profile.

Loading...
Day Range10.53 - 11.3352 Wk Range3.83 - 23.49Open / Close10.65 / 11.28Float / Outstanding48.8M / 49.2M
Vol / Avg.1.1M / 2.3MMkt Cap554.5MP/E-50d Avg. Price10.98
Div / Yield-Payout Ratio-Total Float48.8MEPS-0.48
Globe Newswire - May 16, 2022, 7:30AM
Globe Newswire - Dec 13, 2021, 1:00AM
Globe Newswire - Dec 13, 2021, 1:00AM
Seeking Alpha - Nov 10, 2022, 5:13PM
Seeking Alpha - Nov 10, 2022, 11:10AM
Seeking Alpha - Sep 28, 2022, 8:51PM
TipRanks - Sep 22, 2022, 12:25AM
InvestorsObserver - Sep 20, 2022, 11:40AM
InvestorsObserver - Sep 15, 2022, 7:38AM
InvestorPlace - Sep 14, 2022, 11:14AM
Seeking Alpha - Sep 7, 2022, 8:10AM
Sector: Health Care.Industry: Biotechnology
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV).

Earnings

see more
Q3 2022Est.ActualSurprise
EPS-0.500-0.480 0.0200
REV870.000K2.000K-868.000K
Q2 2022Est.ActualSurprise
EPS-0.510-0.420 0.0900
REV870.000K8.000K-862.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Altimmune (ALT) stock?

A

You can purchase shares of Altimmune (NASDAQ: ALT) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Altimmune (ALT) stock?

A

The latest price target for Altimmune (NASDAQ: ALT) was reported by Goldman Sachs on Thursday, December 1, 2022. The analyst firm set a price target for 20.00 expecting ALT to rise to within 12 months (a possible 77.30% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Altimmune (ALT)?

A

The stock price for Altimmune (NASDAQ: ALT) is $11.28 last updated December 2, 2022, 9:00 PM UTC.

Q

Does Altimmune (ALT) pay a dividend?

A

There are no upcoming dividends for Altimmune.

Q

When is Altimmune (NASDAQ:ALT) reporting earnings?

A

Altimmune’s Q3 earnings are confirmed for Thursday, November 10, 2022.

Q

Is Altimmune (ALT) going to split?

A

There is no upcoming split for Altimmune.

Q

What sector and industry does Altimmune (ALT) operate in?

A

Altimmune is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.